Positive FDA meetings enable Neuren to proceed with INDs for three Phase 2 trials

Retrieved on: 2021-05-31 23:26:15

Tags for this article:

Click the tags to see associated articles and topics

Positive FDA meetings enable Neuren to proceed with INDs for three Phase 2 trials. View article details on hiswai:

Excerpt

Published: Jun 01, 2021. Highlights: Clear and constructive guidance received from pre-IND meetings with the FDA Office of Neuroscience for Phase ...

Article found on: www.biospace.com